how do you create the artificial mrna that does not cause the body to react against mrna?ut she figured i it out. it is great. >> good morning and welcome to the conversation. >> good morning. the drug companies are willing to give this to their patent but how much the politicians think they will gain everything they do they see a dollar in their pockets they will not do anything to help the people. i just want to know how many do it for the good of america in the world? thank you. >> i apologize i did not hear your name. but good morning to you. one of the most remarkable things of thehe biotech industry is people go into work every day and they fail what keeps them going every day? literally. i've been there for 30 years what is so amazing to have the experiment and it doesn'tan work.o what motivates the next day and every single one was to find so the most remarkable thing of this industry is not like making a sandwich you don't know what will come out of your every day and biotech you think about how you run nine experiment. let me test this out, will that work i canno

but mrna had advantages. thing, it was flexible. >> it allows you to adapt very quickly. >> and perhaps most importantly, it was fast. >> you can go really at light speed. the only calm in people's mind. not so much my mind, that is there has never been a vaccine produce with the mrna platform. i guess it was a fear of the unknown. >> pfizer has unmatched resources, and they throw everything they have behind biontech's innovative design, testing not just one, but four candidate vaccines. >> this is my home. this is where i usually am most of the time. this huge infrastructure that was tested and proven was at our finger tips, was really unlimited resources. >> every human sample that's being collected ends up in this machine. so we didn't have to worry about money. we didn't have to worry about is this approach a little cheaper than that approach. all of those considerations were gone. >> the world health organization described coronavirus as the defining health crisis of our generation. >> big pharma firepow

subsequently, the investments by private investors in either and/or moderna and biontech led to the mrna vaccines, and investment, j&j had been investing for years and knew how it could come to table with a similar vaccine. with regards to the loss of what it might mean for the top line of these companies, it is not clear, because october last year, moderna said they would be willing to waive patents, license, and provide vaccines to others. it is not at all clear what they lose in the long term. in the short term, the industry suffers because what happens is people lose confidence that their investments in other companies, cancer companies, diabetes companies, where they are making novel breakthroughs of the same time we see here that have occurred during the pandemic, investor take a double look and say, wait a second, i am investing in a company and suddenly the government will in and take away those patents which allow me to have the certainty that i would investment could give us a good return long term. it is incalculable at the end of the day. the short-term uncertainty could caus

when you do in vitro testing, the vaccines that induce antibodies here in our own country, the mrnas and others, you have a rather significant diminution of multiple fold efficacy in the test tube. but it isn't enough to completely obliterate a certain degree of protection. when you get the j&j, which is the only one that has the field experience with that, you can see that you may not protect as well against symptomatic infection. the efficacy goes down, to about 60% or 65%, but it protects extremely well against advanced disease in the form of hospitalization and death. then you have homegrown variants. the ones in california, the 526 in new york -- the diminution is modest, threefold in the test tube. that is something that is telling us that likely, the vaccines will protect reasonably well. the one that people are asking questions about is the 617 in india. we are collecting data right now in real-time, and hopefully within the next several days to a week, we will be able to make a determination as to what the effect of antibodies induced by our vaccines are against that particu

they've been working on this long before the pandemic so using mrna. you could get the body to make a protein. that protein good debate as herbal effect against cancer. the furthest advances -- mrna vaccines, cancer vaccines and generally they tend to be highly personalized. you can make the vaccine to their very own tumor in a way that will cost them side effects . this is an idea that -- is very promising area and we need to see how it is developed. sen. blunt: in the pandemic particularly with lab closings, we obviously lost some time, maybe less research and it is going to take a long time to re-create. the lamprey openings happening in the weight they need to. do you have the flexibility to extend a grant to overcome the disruption and not just the disruption of the time close but the time, the research lost by closing as well? >> this is yet another one of the terrible casualties of this pandemic. it is been hard on researchers. and yes, we did have to have many of those folks staying away from the workplace for their own safety. they're coming b

the mrna? also, with regard to the trials, i wanted to ask, where do these countries get those trials? if the vaccine has been effective against the additional strains that have occurred, once those people did get the vaccine? host: thank you for the questions. this is from steve. how is work going on protein-based? steve is interested in comparing the effectiveness on sustained antibody levels. your response? guest: there are a few things in there. we all make messenger rna. it is what is used to make proteins. when we were able to sequence the virus, in january of 2020, it is a single-stranded messenger rna virus. if you can make antibodies, the virus cannot bind to the cells and cannot infect you. that is what that is. it is a small piece of genetic material that makes protein and is taken up by certain subtypes that travel to the draining lymph node. this vaccine does induce vigorous response. many people get swelling of lymph node in their armpit. we give a lot of vaccines through shots. i

tom: we remember the skepticism of mrna research and the ability to do this. the bottom line is, celebrate, the home where delivery of this by drug companies centered mostly out of the united states of america. that industry was founded on patent and copyright and intellectual right protection. how do you structure a process so they get compensated? everybody is on this site or that side and nobody is talking about what is the process of solution? i go back to ricardo hausman who says, look, there is a solution. let's get to it. jonathan: professor stiglitz will be on later on this morning. we will have questions for the next several hours. i want to look at the price action briefly. what an interesting market in the u.s. we are very, very focused on what is happening with real yields. they are deeply negative yet tech is not outperforming, the financials are. energy stocks are. lisa, this is a nuanced market. we have a lot to talk about. lisa: but not a snooze fest. that is the distinction to also borrow from tom was not if you look at the inflation breakeven

second dose so this is a study recently published in the new england journal of medicine from the mrna the mass vaccination setting in israel. look at the column on the left looking at infection and symptomatic hospitalization or severe disease although there is a significant degree of protection after the first dose, look at the difference between the first and second dose. forty-six versus 9257 versus 94. this is the study that dr. wolensky just moment mentioned a moment ago look at individual 65 years of age and older where you have an extraordinarily good effectiveness of fully vaccinated seniors at 94 percent but look at the partially vaccinated people again a reasonable amount of protection but not nearly as much as you get from the two doses. next slide. here is a study i showed you had a previous briefing from employees at the university of texas. the unvaccinated looking at the infections they are did not do well they do much better if you are partially vaccinated. but there is a 36 fold difference to get fully vaccinated against partially vaccinated. next slide. >> if you loo

they got the mrna vaccines.seen caseloads come down, but doubts, hospitalizations -- deaths, hospitalizations, and immunity. some of the countries that got the other vaccines, we have not seen that as much, that this will be something going forward that will be very important as countries tried to not only get people vaccinated, but to bring down the spread of infection so they can return to some sort of normalcy. there is also the issue of variants. we did not know yet how these vaccines will protect against variants. we think they protect against some variants, but we will not no more until some studies have been done, and we have the newer variants, like the one in india, where there is very little known about how vaccines work against them. india has not been well-vaccinated, and that is part of the issue. >> which countries are seeing cases rise despite being vaccinated and which child are they using? -- which shots are they using? >> one nation's numbers are not is because you would expect for being, for h

for us all to understand is that both pfizer and moderna, because of the new kind of vaccine types, mrna are able to pivot on a dime and start to think about how to tackle the new variants if they should come along and how they might improve the effect of their vaccines on them. so, we've got a lot of confidence in the way that they are able to at least try to manage new variants. >> speaking of pfizer and moderna, kurt wants to know in a tweet asked to guess what the profit margins are and what is the forecast of their profit margins for those two companies? >> i don't know and i think kurt, haven't talked to the companies and they publish these and i don't follow that specifically but i do know something that without the investment that those companies madeha this country would stille shut down. what would be experiencing, let's not focus on did they make money out of it? i hope they do. let's ask a different question. if they were not here what would we be doing and we would have millions out of work and people who are old would be dine and we know that we don't need to run that exper

the mrna regimen. next slide. if you compare this to other real-world up takes of vaccines that have been around, this report came out a week ago looking at the zoster vaccine in the u.s. from october 2017 to september 2019. it is a two dose vaccine. with the doses coming two and six months after the first dose. 70% to 80% of individuals completed the series which means 20% to 30% have not. thus far the 8%, though you'd like to see 100% adherence, 8% is within the well. of what you see with other multidose vaccines. next slide. let's take a quick look at what the guidelines are that we know about administration. the pfizer gets a single dose and 21 days later did get the boost. for moderna it is 28 days. if it is not feasible to adhere to the recommended interval -- and in the real world there are many reasons why this might not be feasible -- the second dose may be rescheduled for up to six weeks or 42 days after the first dose. so why is there some uncertainty about the importance of second doses? about 44% of a

these led to what is called the mrna vaccines.stment. j&j itself launched a vaccine fn approach. that vaccine approach wast vacc on years of investment. had b it's a different kind of vaccine, but j&j itself had beeo investing for years in vaccines and so knew how it could come to the table with a similar vaccine. with regard to the loss of what might mean for the top line of these companies, it's not aih clear. last year already ense moderna hadd said they would be willing to wave patents, and they would be willing to provide vaccines to others. it's not at all clear what they will lose in the long term.appes in the short term, the industrye suffers because what happens is people lose confidence that their investments in other arem companies, cancer companies, diabetes companies, and others where they are making novel i breakthroughs in the same kind that we see here that have occurred in the pandemic., wh what youy see is that investor take a double look and say, wait, why would i invest in a company if suddenly the government is going to step in and take away those patens whic

>> that's the advantages of mrna vaccines is they're very easy to construct.first vaccines out there in mid-december in this country. and so they're easy to construct. nothing is easy to mass produce. the lipid nanoparticles, so-called fatty droplets in which mrna resides, is not easily scaled up. as you saw, it's not easy to mass produce or mass administer a vaccine. but the deinstruction of the vaccine is not that hard. >> dr. paul moffett, always good, you're one of the outside advisers to the fda on these issues, particularly vaccine and particularly specializing in kids. always good to get your expertise. thank you, sir. >> thank you. >>> and be sure t tune in to our cerebral "vaccinating america." it's a town hall that will be hosted by my colleague lawrence o'donnell. tomorrow at 10:00 p.m. eastern on msnbc. >>> coming up -- new national security concerns after the fbi blames a russian criminal group, not the nation state, but the cyberattack on a major u.s. pipeline. one of the government's top former officials on cybersecurity, christopher krebs, join

the mrna? also, with regard to the trials, i wanted to ask, where do these countries get those trials? if the vaccine has been effective against the additional strains that have occurred, once those people did get the vaccine? host: thank you for the questions. this is from steve. how is work going on protein-based? steve is interested in comparing the effectiveness on sustained antibody levels. your response? guest: there are a few things in there. we all make messenger rna. it is what is used to make proteins. when we were able to sequence the virus, in january of 2020, it is a single-stranded messenger rna virus. if you can make antibodies, the virus cannot bind to the cells and cannot infect you. that is what that is. it is a small piece of genetic material that makes protein and is taken up by certain subtypes that travel to the draining lymph node. this vaccine does induce vigorous response. many people get swelling of lymph node in their armpit. we give a lot of vaccines through shots. i

as senator barrasso said the mrna technology is standing. the vaccines are very effective and what you've essentially done is taken a somewhat cumbersome or very cumbersome biological process and you have transformed into a chemical process that's not easy but much more predictable. the companies are getting better and better at doing it. but the production is nowhere near what's needed for global control and that's what i think what would be most beneficial for the world enter the u.s. would be to expand mrna production capacity in different regions of the world, controlled so it's not a commercial risk to the companies that have invested in this but use new production facilities to get these vaccines which can readily be tweaked if new variants emerge and which are much less susceptible to production, delays and problems to help us get past this pandemic for good globally. >> i'm going to come back to that specific about vaccine manufactured elsewhere in the world, but senator, ethic and first ask about vaccine nationalism. do you agree wi

there isn't the capacity to make mrna vaccines at the scale that the world needs them to be made. and they're very expensive. you know, one could imagine that the vaccines that are successful in the first round of vaccination in the early stages or the acute phases of this, you know, our interactions with the sars 2 virus may not be the ones that are around that will be used year after year or every five years or whatever. i mean, do you see sort of a reckoning and a rationalization of the vaccine landscape coming? .. how to keep those lipid nanoparticles stable at room temperature. >> that does not mean they are developing one with gsa. >> technology will improve. in some ways the spike protein is a soft target. it works against covid 19. the rna technology will not work, and the mark vse technology. a lot of versatility, the opportunities to build up indigenous, developing vaccines and producing vaccines, they are not global importance. no new vaccines are made on the african continent, no new vaccines are made in the middle east with the exception of iran. barely anything is ma

the point is to transfer the technology and the know-how so there can be some platforms producing mrna vaccines in africa. reporter: not everyone is on board, with neighboring germany rejecting the proposal, saying that it would only discourage innovation, and that the focus should be on ramping up reduction capacities. the pharmaceutical industry has also voiced opposition, arguing that such a move would do little to change the status quo of vaccine supply and that it is not a practical solution to the doses.x process of manufacturing that e.u. commission has announced it is open to the idea. >> the european union is also ready to discuss any proposal that addresses the crisis in an effective and magmatic manner. reporter: wto member states will seek to hammer out a deal in the coming weeks. however, it could be months before they reach a consensus. in addition to that, all members will need to unanimously agree to the decision. mark: so the situation regarding the vaccine, joe biden made the initial call. he was common for intellectual property rights to be waivied on the covid vacci

that is why we are anxious to get mrna vaccines donated to india. >> dr. monica gandhi, don't go away. we have a lot more to talk about wi >> all right, coming back, thanks. >>> all right, we are back with ucsf infectious disease specialist, dr. monica ga over on facebook live, we were answering your questions. i want to go back to the strain of moving so thickly in india right now. devastating the country is 1.6.7.2, that is just one. you expect many more variance to come out of india, because the virus is so bad >> so it's true that the most productive factor of variance or mutations occurring is increased transmissibility with this virus. it doesn't actually mutate that fast if you keep pieces low, but if cases are going hi, that's where it can be taken. you are absolutely right, that it depends. all of us getting the epidemic under control in india is good for all of us, worldwide, which is why we are linked together to the coronavirus. we need to work with us all to be safe. >> given that there are many many, do you think one could breakthrough, that

mrna is now very exciting. it's very interesting you have asked the question about where we are with other areas of universal flu vaccine. [laughter] just today -- [laughter] they started a trial on using a mosaic where they have multiple different hemoglobin's, these are the different colors, which are promising. this affects the troublesome component of influenza we are dealing with. a phase one trial called the nano particle mosaic approach to the universal flu vaccine. thank you for axing -- asking that question. . chair delauro: it looks like something i would have in my office as well, dr. fauci. [laughter] thank you. dr. gibbons, this is about cardiovascular disease in women. in 2017, 3 hundred women died as a result of heart disease. -- 300,000 women died as a result of heart disease. heart disease and stroke is the leading cause of death in the united states. critical on research and heart disease. a quick update on nhlbi supported research, and let me go there. i think we need to have more information

to intercede and now a lot of countries jumped on that bandwagon and in materials of the numbers, mrna vaccines are the most cutting edge products in biotech right now, the rocket science of biotechnology production even if they put out the blue prints on the internet tomorrow it would probably take at least a year or more likely two to three years for any company in the world to assemble the team, the infrastructure, the hardware and software to be able to make these. so we're in good shape between the two things the headline risk is real. risk to numbers, almost zero. >> so even if they did that, put it on the internet, they would still have two to three years of sales of the covid-19 vaccine ahead of them? >> correct, correct. we've had other examiples of ths before in the '90s, got the lead with antibody protection and lost the intellectual wherewithal and through raw material they had a supply chain going that was difficult for people to overcome, same story playing out with mrna. >> the efficacy for moderna was a proof of concept moment for its platform for its pipeline basically

that have been working with the mrna for decades. so sharing the know how is part. and third is the funding. even in the george w. bush administration, the u.s. was a leader by putting in the funding of this happening already committed to this global work we have the patents, a gateway to a cascade of things that have to happen. many of us were very stunned today and thrilled to see the message from the ambassador saying the biden administration was over. with he know that is only step having very transparent text-based negotiations that won't overrepresent the needs of the big pharmaceutical companies and ceos and really well-worked pandemic. >> the officer for partners and health, thank you for your time. i think a lot of people in this space were thrilled. thank you for helping us understand. >> you are welcome. thank you for having us on. >> much more ahead tonight, stay with us. so you're a small business, or a big one. you were thriving, but then... oh. ah. okay. plan, pivot. how do you bounce back? you don't, you bounce forwar

we have a lot of experience with this mrna vaccine. >> and dr.ple who say they just don't want to take a vaccine? they're anti-vaxxers, suspicious about putting anything into their bodies. >> yeah, i think this is a concern that a lot of people have and really what they need to do is have these conversations with their health care practitioners. i've told my patients that getting covid-19 and being a part of never having to worry about dying or having a hospitalization from this is incredibly important even as we're still seeing deaths each day, andrea. i think another important point about putting foreign substances in your body, these are not foreign substances that in any way alter anything other than provoking your own immune system to develop responses to deal with the viruses. and, in a way, i try to explain these viruses themselves can cause more harm by being in your body. we are still trying to unpack the long-term effects of covid-19, and it's likely it will be years before we understand what this really means. so, in short, get your va

most of the data that we have is related to the mrna, either the pfizer/biontech or moderna.ut if you look at overall efficacy's, all three of them are highly effective vaccines. what we don't know is the question you are asking. did we compare this vaccine with this vaccine as to whether or not asymptomatic infections and transmitter not? we just don't have that data. david: do we have data about how long my vaccination is going to be effective? you recently said we may have to have booster shots every year. we have a sense of exactly how long this is going to be of? -- going to be effective? dr. fauci: we don't know. i made that statement, but probably it was a little bit misinterpreted. i am not sure we will need a booster. we might. and if so, i don't know at what point following the vaccinations we will need it. i think that is still uncharted waters. but what we are doing to try to get a reasonable answer to your question is we are following people from the original clinical trials and looking at the level of laboratory indicator of protection, which is the level of you

when you look at the immune response to a single dose of mrna vaccines in organ transplant or cancer patients, very very clearly the single dose was not adequate. this becomes important because organ transplant particularly individuals on a variety of immunosuppressant drugs and cancer patients but there are a lot of people in society on things like glucocorticoids, that may not get a good enough response after the first dose and we want them to get the second dose. let's look at the data that backs up this clinical, next slide. i showed you the slide before, we are looking at neutralizing antibodies after the first dose which is at 21 days versus the second dose which is at day 28-35. as you can see regardless of age younger individuals or older individuals, dramatic difference in neutralizing antibodies between the first and second dose, next slide. we talk about t cell responses, same thing. if you look at after the first dose, day 29 on the t h1 response to the spike protein and at the responses that day 29 versus 43 which is after the second dose, yet again another important dif

. >> reporter: after receiving a mrna vaccine, people with normal immune systems produce the antibodies against the virus that causes covid, but research finds after being fully vaccinated, half of transplant patients have no antibodies at all and he recommends that even those taking less powerful medication consider having the antibody level wills tested. >> it's not unreasonable to seek data in the form of a reliable antibody test that you discuss wi y ctor >> reporter: that's because it's still not known how much protection covid-19 vaccines >> reporter: the medication mcma mcmanis takes, stops her immune system from attacking her own joints. >> my doctor keeps a close eye on me. so he the did an antibody test on me. >> reporter: what did it show? >> it shows i have no antibodies. >> reporter: what did you say too your husband? >> i'm going have to get the vaccine again. and his response was, well, you get a flu shot every year. >> reporter: she is getting a third vaccine doses to stimulate her immune response. the same strategy chosen by dr. montgomery. how many days after that shot

mrna is now very exciting. it is very interesting you asked that question about where we are with other areas of universal flu vaccine. just today, we started a trial of the nanoparticles using the mosaic where we you have -- we have multiple different hemoglobin's that are promising because we have four or five different gluten to cover the waterfront of these troublesome influenza components that we are dealing with. we just started a phase one trial caught and nano particle mosaic approach to a universal flu vaccine. thank you. if you have questions, this is what it looks like. ms. delauro: it looks like something i would have in my office, as well, dr. fauci. thank you. thank you. dr. gibbons, this is about cardiovascular disease in women. 300,000 women died as a result of heart disease in 2017. heart disease and stroke -- leading cause of death of women in the united states. critical research on heart disease could update nhlbi's supportive research. let me go there. and let me go there. i think we need to

they are arguing it doesn't help if we had a waiver for the patent of mrna-based vaccine, which, of course from biontech and moderna this is not that easy to replicate the vaccine. just by waiving a patent is potentially disrupting supply chains for the ingredients for the vector 1 and mrna-based one. that is their approach they are saying we should boost production and export more instead of trying togive the patent away for free german chancellor angela merkel is at the forefront to say it is not the way she wants to go. her primary goal is to protect intellectual property. take a listen. >> translator: i made clear i don't believe releasing patents is the solution to providing vaccines for more people rather, i believe we need the creativity and ability to innovate companies for me, patent protection is part of that it is all about the question of how we can get as many vaccines to as many people in the world in the shortest period of time for that, licenses have to be granted. what i know from german companies, that is happening in a timely manner in huge quantities >> if you talk to a

the basic scientific research accompanies -- like pfizer and others are going to be -- >> mrna. >> mrnara: that is hard to say. >> a boy. >> laura: raymond, i watched every minute of today and i'm sorry, the gas shortages are scary. that's terrifying. what else? >> i agree. especially for the nurse standing by. anyway, speaking of stumbles, the golden globes have really fallen off its axis. nbc has decided not to air the award show next year. netflix and amazon are distancing themselves from the hollywood foreign press association that runs the golden globes until they diversify their membership and welcome more black members. tom cruise returned his three golden globes in protest, so i got a good deal at a malibu garage sale the other day. >> laura: you got your -- there you are. good for you! they look good on you, raymond, fantastic. he should have given them back just for being a lousy actor. i'm just kidding, totally kidding, tom. other stars are speaking out as well. >> the h fpa is something that has been around since i kind of came in and they are kind of a unique and eccentric

the mrna vaccines from pfizer and moderna do not appear to pose any-serious risk during pregnancy. to preliminary findings published in the new england journal of medicine. but the cdc says pregnant women who get covid are at an increased risk for severe illness, preterm birth, and maternal death. i always talk to my patients about the risk-benefit calculus. we know that there are real risks. if you're pregnant and you get sick with covid. in my mind, the benefits outweigh the risks. >> claims that are made about this vaccination, particularly, do target women. >> right. they target women. it's funny, because the hesitancy that's shown amongst males as more politically charged. that's what i've seen. >> reporter: we were set to interview multiple women who told us they don't want the vaccine but they all bailed. some saying they feared backlash. that's not an irrational fear. there is a lot of shaming on social media which public-health experts say doesn't work. some of their friends wouldn't talk on camera. neither would women cnn spoke to in public parks. influencers turned us do

how does that affect the making of the medicine, not who owns the mrna or what is in the shop, but thehat is in the shot, but the actual manufacturing process? sam: it highlights the complacency of the process if you have 200 elements you can patent. india is the biggest manufacture vaccines worldwide. why haven't they done the work already? this is a failure of state rather than industry. the company has had access to the astrazeneca vaccine technology for quite a while. it just shows it is not that simple to make these things. lisa: let's put aside the procedural aspect of creating the vaccine and go to the money behind this. a question of pharmaceutical companies that say we created this, we should get the money, otherwise what is our incentive to create new drugs that are better and greater and can help the public good. joseph stiglitz was just on talking about how this is hogwash and the government financed a lot of the production of these vaccines. what is your take on that? sam: that may be true. i'm not going to say anything to negate what our esteemed speaker said earlier. the

as senator barrasso said the mrna back technology is stunning. what you've essentially done is taken a somewhat cumbersome biological process and you've transformed it into a legalprocess . it's not easy but much more predictable and the companies are getting better and better at doing it but the production is nowhere near what's needed for global control and that's why i think what would be most beneficial to the world and to the us would be to expand mrna production capacity in different regions of the world. control it so it's not a commercial risk to the companies that have invested in this but use you new production facilities that new variants emerge and are much less susceptible to production delays and problems to help us get past this pandemic for good globally >> i'm going to come backto that point specifically vaccine manufacturing in the world . but senator if i could first ask you about vaccine nationalism as a concept in and of itself. do you agree it'sinevitable but it's not a good thing ? >> we can discuss whether it's a good thin

to each office gets what's called mrna, the allocation to the office of their budget. we are trying to pull some things out of the mrna. things like the basic technology investments. potentially things like you know when you do telephone town halls, can we get one big contract for congress rather than having each member of the office pay for that out of there are a with the notion that that could create capacity to pay staff better. we also though acknowledge that pay is not the only part of this. benefits as part of it as well. it's in my view completely bonkers that the district staff that i have here at the state of washington are currently required to be on the d.c. health exchange. one of our recommendations was knock that off. it doesn't make sense. they're the only workers in the state of washington who are required to be on the washington d. c held exchanged so either letting staff beyond their own states exchange or be part of the fta b h like every federal employee makes some sense, the other thing that we've heard is a desire for when people come into congre

these mrna vaccines are pretty amazing.itial work even at the recent hiv meeting that mrna vaccines could provide hope for being the vaccine. i think you will see a huge amount of research on this. learning from covid and applying it to hiv. >> an incredible conversation. a.i.d.s. walk starts at 10:00 a.m. this year's virtual event will stream online and on abc7. we are proud sponsor of the event which will pitcher billy porter, rita moreno, rosie perez, ben platt, george takei and many more. proceeds benefit 35 service organizations across the bay area. there is time to register and raise funds today. we hope you take part. visit sf.aidswalk.net or call the number on your screen. dan ashley is there live and we will bring more at 10:00 a.m. >>> two young developers in san francisco are getting attention on the world stage. college seniors are finalists in microsoft's imagine cup. their students at san francisco's minerva schools at the graduate institute. they moved on after winning the education for developing remote labs

the mrna vaccine fs from pfizer and moderna does not post any risk. >> i always talk to my patients aboutknow there are real risk, if you are pregnant and you get sick with covid. in my mine d, the benefitsout w the risk. >> they target women. >> it is funny because the he has hesitancy shown among males are more politically charged. >> reporter: we were set to interview many women that they don't want the vaccine. there is a lot of shaming on social media which polublic he' experts say does not work. women would not talk on camera. influencers turned us down. we went to an outlet mall and found this one woman. >> are you going to take the covid-19 vaccine. >> absolutely no because i am pregnant. i heard a lot of stories about people losing a baby. er >> reporter: what kind of story? >> where do you get news about that? >> it was an article. i am not sure. >> reporter: what did your doctor say about the vaccine. >> she have not said anything, i have not asked her about it. i am being precaution right now. >> reporter: it is understandable to be hesitant. i beat that he hasitancy with know

with mrna for decades, so sharing know-how is second important thing.ird is really the funding. we saw that even in the george w. bush administration, the u.s. was a leader in global aids by putting in the funding for this to happen. interestingly there's already $16 billion committed to global work on covid-19 vaccine. so the money is there, we hope the u.s. will continue to put money into this effort. we need the know-how shared, raw materials and patents. patents are one step but a major step. they're a gateway to a cascade of things that have to happen. and many of us were very stunned today, and very thrilled to see the message from ambassador ty saying that biden administration would support the waiver, but we know that's only one step. and right now what we're focused on is really having very transparent text-based negotiations that we're all able to see that won't overrepresent the needs of the big pharmaceutical companies or ceos and really will work to end the pandemic. >> chief medical officer for partners in health, thank you so much for you

mrna technology before the plague has been accelerated.robotic drone delivery technology before the plague has been accelerated. there are a variety of ways over the short term there were some changes in our society. in education, real estate, people work from home, reshape the real estate market in interesting ways. in terms of these other technologies that i mentioned, long-term i don't think there will be radical changes. short-term there will be a number of them in various parts of our economy and social life. >> patty and janet, we won't have that to get to. both of these gentlemen are on twitter so you can tweet at them. you can look at their handles on my twitter page which is@-- you can share your handle or however else. if either of you have ways to get in touch. >> we have -- few google us. >> >> thank you for your time, this was an interesting conversation. no more bookshop to get copies for yourself, thank you gentlemen, let me say that i more time, apollo's arrow, the effect of the coronavirus on the way we live by nicholas ch

however, it was ante dated by decades of research on the platform technology such as the mrna as wells of research on coronaviruss and other viruss to give you a very po potent vaccine. things did not start on january 2020. january 2020 was the culmination of decades of research. a few more quick questions including this one from a viewer about travel. the viewer asks, i have family living in europe in the netherlands that i would love to hug again. do you forsee a lift in the travel ban with europe or vaccine passports in the near future? we know the g20 country start contemplating passport. some kind of proof of vak si nation for international travel. what do you see? >> certainly there's not going be vaccine passports that will be at the federal level. there might be airlines that will require showing proof of va vaccination. there may be companies that require it. we know that colleges are already talking about a requirement for veriication of vaccination. it's not going to be federally mandated. if you go to see a relative where ever they may be, yes, absolutely. you can be in th

waving intellectual property rights -- you don't snap your fingernd have a plan the that produced mrnaial supply constraint today, it's about high-quality manufacturing to gmp standards, it's about raw material supply and finish in a sterile environment. there's a lot of technically complex things here that are not going to be solved just by waving intellectual property the u.s. government wanted to assist in providing these vaccines to poorer countries they should have helped to invest in manufacturing here in the united states, created jobs here in the united states and we could have supplied those vaccines at profit or nonprofit or for free. >> brent, it's karen, i appreciate your thoughts let me just ask you so moderna was supported by the government in their efforts and pfizer wasn't yet both seem to be hurt by this. is there any fix you can think of that would work politically, but still allow them to certainly at least pfizer anyway to benefit >> well, i think -- i think -- look, i haven't spoken to either ceo but i think most in this industry in biopharmaceutical industry want

these mrna vaccines are pretty amazing.en at the recent meeting that mrna vaccines could provide hope for being that vaccine. i think you will see a huge amounts of research learning from covid and applying it to hiv. >> that was a really beautiful conversation. thank you to reggie for that. a.i.d.s. walk starts and i was at 10:00 a.m. this year's virtual event will stream online and right here on abc7. we are at proud sponsor featuring billy porter, rita moreno, rosie perez, ben platt, george takai and many more. proceeds benefit service organizations across the bay area. there is still time to register and raise funds. you can call the number on your screen. we will be live at robin williams meadow and golden gate park to kick things off this morning. we are excited to have them join us at our 9:00 show. it begins at 10:00 a.m. right here on abc7 . >>> next from the bay area to the big stage. two local co it's the memorial day sale on the new sleep number 360 smart bed. it's the most comfortable, dually-adjustable, foot-w

within one year, we made these mrna vaccines a novel technology, remarkably safe, remarkly effective,n't have that administration embracing it. i don't get that. the republicans should be beating their chest talking about the amazing accomplishment they've made, but they don't. >> can i ask you. you bring up how remarkable this is. to compare it to and say even the development of the polio vaccine is stunning, is this vaccine now going to change the game foing gore ward for so many other vaccines especially in terms of speed of development? >> well, i'm not sure in terms of speed of development. when the government puts forwarded 24 billion -- >> that helps. >> i think for vaccines like a tuberculosis vaccine or universal flu vaccine, malaria vaccine, there will be studies looking at the mrna technology and see if it applies to those pathogens. >> i have some of that in my bloodstream right now. >> a new group able to be vaccinated are kids 12 to 15, 16 and up. as you see kids vaccinated, the us that help fill the gap in the number describing there in terms of getting the country to e

the mrna vaccines from pfizer and moderna do not appear to pose any serious risk during pregnancy.ing to preliminary findings published in the new england journal of medicine. the cdc says pregnant women who get covid are at increased risk for severe illness, pre-term birth and maternal death. >> i always talk to my patients about the risk/benefit calculus. we know there are real risks if you're pregnant and you get sick with covid. and in my mind, the benefits outweigh the risks. >> claims that are made about this vaccination particularly, do you target women? >> right, they target women. >> it's funny because the hesitancy that's shown amongst males is more politically charged. that's what i've seen. >> we were set to interview multiple women who told us they don't want the vaccine. but they all bailed. something they feared, backlash. that is not an irrational fear. there is a lot of shaming on social media which public health experts say does not work. some of marlene's friends wouldn't talk on camera. neither would women cnn spoke to in public parks. influencers turned us down

particularly the mrna vaccines, the technology is complicated.are over 50,000 steps required to make these vaccines. there are specific limitations on the equipment available to make these vaccines, including certain kinds of filters and so forth. the companies have already stated they would be willing to share what they can and what is needed around the world if in fact we saw the capability there. we are challenged right now with india, which has been counted on as a major partner given their production capability, but now since we have seen this very serious challenge in india, vaccines have been rented from leaving the country, so again, india has a real need. they need to get vaccines but the world needs to get vaccines. there is a great deal of discussion going on right now, how best to approach this as quickly as possible ways to scale up vexing availability around the world, and it is high priority. haidi: it has been the essence of this since the very beginning. we saw an independent panel review of the global audit response saying w.h.o